Companies / Biotechnology
Equillium doses first EQ504 subject, triggering $20 million closing and cash runway into 2029
Australia's Phase 1 study plans to enroll about 70 healthy volunteers at 0.1 to 3.0 mg a day, with topline data anticipated in the second quarter of 2027. The $20.0 million tranche is priced at $0.57 a share.